Panelists explore how treatment goals differ between primary and secondary cardiovascular prevention, emphasizing risk stratification, guideline application, and strategies to optimize long-term outcomes through individualized, multidisciplinary care.

Panelists examine how LDL-C targets vary by cardiovascular risk level and highlights the role of pharmacists and multidisciplinary teams in delivering effective patient education to improve adherence and long-term outcomes.

Learn how CAC scans, PREVENT ASCVD scoring, and Lp(a) testing sharpen risk talks and guide statin choices in pharmacy practice.

Learn how CAC scores, PREVENT ASCVD, and Lp(a) reshape risk talks—help pharmacists personalize statins, targets, and follow‑up.

Cardiovascular experts discuss how to assess statin intolerance, expand prescribing of non-statin LDL-C–lowering therapies to primary care and pharmacy teams, and monitor for adverse events in clinical practice.

Learn how clinicians tailor add-on lipid therapies—PCSK9s, ezetimibe, bempedoic acid—using shared decisions, follow-up, and statin myths.

Pharmacists speed cholesterol guideline adoption through patient education, prior auth support, and adherence fixes for

Pharmacists drive new cholesterol care: educate patients, tackle prior auth and cost barriers, and improve adherence to statins and

Experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Pharmacists unpack easier access to PCSK9 inhibitors and inclisiran—smart prior auth, Medicare Part B nuances, and foundation help that cuts costs.

Pharmacists step into cardiovascular prevention with patient education, statin protocols, and new prescribing training—if clinical work gets paid.